Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
Senators Urge CFIUS Review of UAE Investment in Trump-Linked Crypto Firm World Liberty Financial 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
Valero Energy Expands Venezuelan Crude Imports as U.S. Sanctions Ease 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
Anduril Eyes $60 Billion Valuation in New Funding Round to Expand Defense Manufacturing and Autonomous Fighter Jet Development 
Paramount Skydance Appoints Rene Augustine as SVP of Global Public Policy Amid Warner Bros Takeover Battle 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings 
RALEIGH, N.C., Nov. 03, 2017 -- INC Research/inVentiv Health (Nasdaq:INCR), the only fully integrated biopharmaceutical solutions organization, today announced that Chief Executive Officer Alistair Macdonald is scheduled to present at the Jefferies 2017 London Healthcare Conference. Mr. Macdonald’s presentation is scheduled for Thursday, November 16, 2017 at 10:00 a.m. GMT.
Links to INC Research/inVentiv Health’s live presentation and archived audio replay, as well as the presentation materials, will be available via the Company’s Investor Relations website at investor.incresearch.com.
About INC Research/inVentiv Health
INC Research/inVentiv Health (Nasdaq:INCR) is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to address new market realities where clinical and commercial share expertise, data and insights to accelerate biopharmaceutical performance. With more than 22,000 employees and the ability to support customers in more than 110 countries, our global scale and deep therapeutic alignment enables INC Research/inVentiv Health to help customers successfully navigate an increasingly complex environment. For more information on our Raleigh, N.C.-based company, visit incresearch.com or inventivhealth.com.
| Investor Relations Contact: | Press/Media Contact: | |
| Ronnie Speight | Danielle DeForge | |
| Vice President, Investor Relations | Senior Director, External Communications | |
| +1 919 745 2745 | +1 781 425 2624 | |
| [email protected] | [email protected] |
